ArticleJournal of internal medicine2022
Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Droplet Digital PCR or Real-Time PCR as a Method for Quantifying SARS-CoV-2 RNA in Plasma-Is There a Difference?Viruses · 2025Article
- Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies.Scientific reports · 2025Article
- Regulatory cytokines modulate early isotype-specific response associated with COVID-19 survival.Frontiers in immunology · 2025Article
- Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland.NPJ vaccines · 2024Article
- Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.Qatar medical journal · 2024Review
- Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort.Scientific reports · 2023Article
- Article
- Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma.Diseases (Basel, Switzerland) · 2023Article
- IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes.Respiratory research · 2023Article
- Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2- seropositive individuals.The journal of allergy and clinical immunology. Global · 2023Article
- High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection.International journal of environmental research and public health · 2022Article
- N-antigenemia detection by a rapid lateral flow test predicts 90-day mortality in COVID-19: A prospective cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19.Critical care (London, England) · 2022Observational
- Presence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus-2 on Admission Is Associated With Decreased Mortality in COVID-19 Critical Illness.Critical care explorations · 2022Article
- SARS-CoV-2-reactive IFN-γ-producing CD4Scientific reports · 2022Article
- Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients.Scientific reports · 2022Article
- Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.The Lancet. Microbe · 2022Article
- Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units.Archivos de bronconeumologia · 2022Observational
- Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 8 institutions in 3 countries.
María Martin-VicenteUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
Raquel AlmansaGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Isidoro MartínezUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
Ana P TedimGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Elena BustamanteGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Luis TamayoGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
César AldecoaGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
José Manuel GómezIntensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
Gloria RenedoIntensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
Jose Ángel BerezoGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Jamil Antonio CedeñoIntensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
Nuria MamolarIntensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
Pablo García OlivaresIntensive Care Unit. Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, Madrid, Spain.
Rubén Herrán-MongeGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Ramón CicuendezIntensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
Pedro EnríquezGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Alicia OrtegaGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Noelia JorgeGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Cristina DoncelGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Amanda de la FuenteGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Juan Bustamante-MunguiraDepartment of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.ORCID 0000-0002-6542-4504
María José Muñoz-GómezUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
Milagros González-RiveraDepartment of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Carolina PuertasDepartment of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Vicente MásUnidad de Biología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
Mónica VázquezUnidad de Biología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
Felipe Pérez-GarcíaServicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Madrid, Spain.ORCID 0000-0002-4885-4334
Jesús Rico-FeijooGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Silvia MartínGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.
Anna MotosCentro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Laia Fernandez-BaratCentro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Jose María EirosMicrobiology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
Marta Dominguez-GilMicrobiology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud, Valladolid, Spain.
Ricard FerrerCentro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Ferrán BarbéCentro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Wysali TrapielloClinical Analysis Service, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud, Valladolid, Spain.
David J KelvinDepartment of Microbiology and Immunology, Faculty of Medicine, Canadian Center for Vaccinology CCfV, Dalhousie University, Halifax, Nova Scotia, Canada.
Jesús F Bermejo-MartinGroup for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Salamanca, Spain.ORCID 0000-0002-7998-6268
Salvador ResinoUnidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.ORCID 0000-0001-8783-0450
Antoni TorresCentro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Instituto de Salud Carlos III · ESInstituto de Investigación Biomédica de Salamanca · ESHospital Clínico Universitario de Valladolid · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario Río Hortega · ESDalhousie University · CAHospital Universitario Príncipe de Asturias · ESUniversidad de Valladolid · ES
Funding
Atlantic Genome/Genome CanadaCanada Research Chair in Translational Vaccinology and InflammationCIHR CIHR OV2 - 170357Dalhousie Medical Research FoundationGerencia Regional de Salud de Castilla y LeónInstituto de Salud Carlos III CD018/0123Instituto de Salud Carlos III COV20/00110Li-Ka Shing FoundationResearch Nova Scotia
Abstract
backgroundAnti-SARS-CoV-2 S antibodies prevent viral replication. Critically ill COVID-19 patients show viral material in plasma, associated with a dysregulated host response. If these antibodies influence survival and viral dissemination in ICU-COVID patients is unknown. PATIENTS/
methodsWe studied the impact of anti-SARS-CoV-2 S antibodies levels on survival, viral RNA-load in plasma, and N-antigenaemia in 92 COVID-19 patients over ICU admission.
resultsFrequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality (adjusted HR [CI 95%], p): (S IgM [AUC ≥ 60]: 0.44 [0.22; 0.88], 0.020); (S IgG [AUC ≥ 237]: 0.31 [0.16; 0.61], <0.001). Viral RNA-load in plasma and N-antigenaemia predicted increased mortality: (N1-viral load [≥2.156 copies/ml]: 2.25 [1.16; 4.36], 0.016); (N-antigenaemia: 2.45 [1.27; 4.69], 0.007).
conclusionsLow anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. Our findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2.
Indexed as
COVID-19Antibodies, ViralAntigens, ViralCritical IllnessHumansRNA, ViralSARS-CoV-2Antibodies, ViralAntigens, ViralRNA, ViralantibodiesantigenaemiaCOVID-19mortalityRNA
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.